Scientists investigated the potential of domatinostat, a new class I histone deacetylase inhibitor, currently in clinical development, to sensitize PDAC to first line standard gemcitabine/taxol doublet chemotherapy treatment.
[Journal of Experimental & Clinical Cancer Research]
Sorry, but the selected Zotpress account can't be found.
